Related Experiment Videos
[Study on the pathogenesis of acquired pure amegakaryocytic thrombocytopenic purpura]
1Research Section of Hematology, Affiliated Hospital, Nantong Medical College, Nantong 226001.
Objective:
To investigate the possible pathogenesis of acquired pure amegakaryocytic thrombocytopenic purpura(APATP).
Methods:
Twenty eight patients with APATP were studied. Bone marrow mononuclear cells(MNCs) from these patients were plated into methyl cellulose cultures for CFU-GM, CFU-E and CFU-MK assay. The influence of depleting T cells or adherent cells from patients' marrow cells on CFU-MK growth was observed. The humoral inhibitory effect on CFU-MK was determined by co-incubation of patients' sera or IgG with normal or autologous MNCs prior to cultures. The serum MK-CSA was also assessed.
Results:
Fifteen cases (53.6%) of APATP was resulted from intrinsic defect of CFU-MK. The megakaryocyte colony formation was augmented significantly in 3 T lymphocytes-depleted and 2 mono-macrophages depleted patients. Sera from 6 patients(21.4%) were inhibitor to CFU-MK. The inhibitor originated from IgG and selectively directed against the megakaryocyte. In the remaining 2 cases, the pathogenesis was not ascertained.
Conclusion:
The intrinsic defect of megakaryocyte progenitor cell is considered to be a primary pathogenesis of APATP. In some patients the disease can result from abnormal immune mechanisms. The decompensation of MK-CSA production could also be an important cause for APATP.
Insights
Acquired pure amegakaryocytic thrombocytopenic purpura (APATP) often stems from intrinsic defects in megakaryocyte progenitor cells. In some cases, immune system dysfunction or reduced megakaryocyte colony-stimulating activity (MK-CSA) also contributes to APATP pathogenesis.
Area of Science:
- Hematology
- Immunology
- Pathogenesis
Context:
- Acquired pure amegakaryocytic thrombocytopenic purpura (APATP) is a rare bleeding disorder.
- Understanding the underlying causes of APATP is crucial for effective treatment.
Purpose:
- To investigate the pathogenesis of acquired pure amegakaryocytic thrombocytopenic purpura (APATP).
- To identify the cellular and humoral mechanisms contributing to APATP.
Summary:
- A study of 28 APATP patients revealed intrinsic defects in megakaryocyte progenitor cells (CFU-MK) in 53.6% of cases.
- Immune mechanisms, including T-lymphocyte or monocyte-macrophage mediated inhibition and autoantibodies (IgG) targeting megakaryocytes, were identified in some patients.
- Reduced megakaryocyte colony-stimulating activity (MK-CSA) may also play a role in APATP development.
Impact:
- This research clarifies the multifactorial etiology of APATP, differentiating between intrinsic progenitor defects and immune-mediated damage.
- Findings guide further research into targeted therapies for APATP based on its specific pathogenic mechanism.